1990
DOI: 10.1016/0002-9149(90)90207-h
|View full text |Cite
|
Sign up to set email alerts
|

Clinical safety profile of sotalol in patients with arrhythmias

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

3
58
0

Year Published

1994
1994
2019
2019

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 140 publications
(61 citation statements)
references
References 19 publications
3
58
0
Order By: Relevance
“…As discussed further below, antiarrhythmic drugs with QT interval prolonging potential carry a 1 to 3% risk of TdP over 1 to 2 years of exposure (Soyka et al, 1990;Hohnloser et al, 1995;Torp-Pedersen et al, 1999), with the exception of amiodarone. diLQTS also occurs with drugs not prescribed for cardiovascular indications, and the incidence seems orders of magnitude lower.…”
mentioning
confidence: 99%
“…As discussed further below, antiarrhythmic drugs with QT interval prolonging potential carry a 1 to 3% risk of TdP over 1 to 2 years of exposure (Soyka et al, 1990;Hohnloser et al, 1995;Torp-Pedersen et al, 1999), with the exception of amiodarone. diLQTS also occurs with drugs not prescribed for cardiovascular indications, and the incidence seems orders of magnitude lower.…”
mentioning
confidence: 99%
“…The incidence of Torsades de Pointes with both the acute intravenous form as well as the chronic oral route of amiodarone is quite rare (<2%). Torsades de Pointes, on the other hand, has been demonstrated to be quite common in patients receiving chronic oral sotalol (2-4%) [11][12][13] . This is primarily due to its effect on QTc prolongation.…”
Section: Discussionmentioning
confidence: 99%
“…Characteristics such as female gender, history of ventricular dysrhythmias and left ventricular dysfunction, greater magnitude of QT-interval prolongation, and hypokalemia increase the risk of TdP in patients given oral sotalol. 1,[17][18][19] If subgroups of included patients were described in sufficient detail, the characteristics of each subgroup were described.…”
Section: Methodsmentioning
confidence: 99%
“…Chronic oral administration of sotalol is associated with a 2-4% risk of torsades de pointes (TdP). [17][18][19] By definition, TdP occurs in association with a prolonged corrected QT (QTc) interval. Other factors that may contribute to its occurrence include an increase in inhomogeneity of repolarization, which may manifest SOTALOL Marill, Runge • IV SOTALOL AND TORSADES DE POINTES as increased dispersion of the QTc interval, [20][21][22] and the presence of early afterdepolarizations (EADs).…”
mentioning
confidence: 99%